Latham & Watkins Reps Eli Lilly In Alnara Acquisition
The companies did not disclose the financial terms of the deal, which is subject to customary closing conditions including antitrust review.
Cambridge, Mass.-based Alnara develops protein therapeutics to treat metabolic diseases.
The company's lead product is liprotamase, a nonporcine pancreatic enzyme replacement therapy that is currently under review by the U.S. Food and Drug Administration for the treatment of exocrine pancreatic insufficiency, which can be...
To view the full article, register now.